Approximately 75% of breast cancers express estrogen receptor α (ERα) and depend on estrogen signals for continued growth. Aromatase inhibitors (AIs) prevent estrogen production and inhibit estrogen receptor signaling, resulting in decreased cancer recurrence and mortality. Advanced tumors treated with AIs almost always develop resistance to these drugs via the up-regulation of alternative growth signals. The mechanisms that drive this resistance-especially epigenetic events that alter gene expression-are however not well understood. Genome-wide DNA methylation and expression analysis of cell line models of acquired aromatase inhibitor resistance indicated that prostaglandin E 2 receptor 4 (PTGER4) is up-regulated after demethylation in resistant cells. Knockdown and inhibitor studies demonstrate that PTGER4 is essential for estrogen independent growth. Analysis of downstream signaling indicates that PTGER4 likely promotes AI resistance via ligand independent activation of the ERα-cofactor CARM1. We believe that we have discovered a novel epigenetic mechanism for altering cell signaling and acquiring endocrine therapy resistance. Our findings indicate that PTGER4 is a potential drug target in AI resistant cancers. Additionally, the epigenetic component of PTGER4 regulation suggests that further study of PTGER4 may yield valuable insights into how DNA methylation-targeted diagnoses and treatments can improve AI resistant breast cancer treatment.
Introduction
Estrogen receptor α (ERα) is necessary for normal human breast development due to its role in processing estrogen growth signals. About 75% of breast tumors express and depend upon ERα [1] [2] [3] . Endocrine therapies that disrupt estrogen-ERα binding have a long record of clinical efficacy.
Endocrine therapies can be divided into two broad classes: 1) selective estrogen receptor modulators (SERMs) that competitively inhibit estrogen binding to ERα, and 2) aromatase inhibitors (AIs) that prevent the synthesis of estrogen 3 . AIs decrease recurrence and mortality in post-menopausal women when compared to SERMs, such as tamoxifen 4 . Despite this increased efficacy, resistance to AI therapy occurs in nearly all of the advanced or metastatic tumors often through the activation of ligand-independent ER signaling 5 .
Genetic analysis of both patient tumors and cell line models have revealed several mechanisms of acquired AI resistance 5 . Genomic alterations such as amplifications, mutations, or translocations can activate ESR1 in low estrogen conditions 6, 7 . Ligand-independent ERα activation can also occur through activation of the PI3K and MAPK signaling pathways at the cell membrane 8 . Activating mutations in the PI3K and MAPK pathways are frequently found in ERα-positive breast cancers 9 . MAPK signaling required for estrogen-independent growth can also be activated by upstream factors such as silencing of the cyclin-dependent kinase CDK10 10 .
The downstream effectors of these pathways are responsible for phosphorylation of ERα, which activates it in the absence of estrogen 11, 12 .
Despite improved understanding of potential genetic mechanisms leading to acquired AI resistance, potential epigenetic mechanisms of resistance are not well explored. Almost all cancers exhibit altered DNA methylation, an epigenetic mark that contributes to cancer development 13 and progression 14 . Epigenetic studies of endocrine therapy resistance have mostly focused on the direct silencing of ESR1 mediated by either DNA methylation or histone deacetylation [16] [17] [18] [19] [20] [21] [22] [23] . However, less is known about how epigenetic changes might contribute to the regulation of transcriptional networks in the development of acquired AI resistance.
In this work, we hypothesized that changes in DNA methylation contribute to acquired endocrine therapy resistance. Resistance to estrogen withdrawal was modeled in ERα-positive cancer cell lines that have been subjected to long-term estrogen deprivation (LTED) 24 . LTED cell line models have facilitated the identification of mechanisms of acquired endocrine therapy resistance including increased ERα expression 7 as well as increased signaling through PI3K, AKT, and MAPK [24] [25] [26] . They also have been used to show that PI3K pathway inhibitors induce cell death in ERα-positive cell lines with oncogenic PI3K mutations, suggesting that targeting the PI3K pathway may improve treatment options for a subset of women 24, 25 .
Genome-wide methylation and expression analysis of LTED cells identified hypomethylation
correlated with increased expression of the prostaglandin E 2 receptor 4 gene (PTGER4) in LTED cells. EP4, the PTGER4 gene product, is a G-protein coupled receptor that activates adenylyl cyclase (AC) and protein kinase A (PKA) in response to prostaglandin E 2 27 . We find that EP4 activity is necessary for the proliferation of LTED cells. We also show that EP4 up-regulation likely exerts its proliferative effect through PKA-mediated activation of CARM1, which in turn acts as a co-activator with ERα to promote ligand-independent activation of ER-response genes.
The significance of these molecular studies elucidating how EP4 is required for estrogen-independent growth was further demonstrated in the identification of PTGER4 up-regulation in AI-resistance breast tumor samples. The loss of methylation and activation of PTGER4 represents a possible mechanism of acquired endocrine therapy resistance that can be therapeutically targeted.
Results

DNA methylation is altered in a model of acquired resistance to endocrine therapy.
To understand potential epigenetic causes of acquired resistance to endocrine therapy, we performed genome-wide methylation and transcriptome analysis in the MCF7 cells conditioned to grow in the absence of estrogen (MCF7-LTED, long-term estrogen deprived) (GSE45337, GSE74943; GSE45337 is public, reviewer link for GSE74943:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=ubihoogupjsljah&acc=GSE74943). Since MCF7 cells do not express aromatase (as verified by our RNA-seq data), aromatase inhibitor resistance is modeled by estrogen withdrawal. After the removal of estrogen, most cells die;
however, a few survive and eventually begin to proliferate in the absence of estrogen ( Fig. 1a ) 24 .
Genome-wide methylation analysis using Methyl-MAPS 28 indicated genome-wide hypomethylation in MCF7-LTED compared to MCF7 cells with 245 644 CpG sites losing methylation and 28 751 sites gaining methylation. Analysis of these sites indicates that the majority of these changes occurred in the transposable elements ( Supplementary Fig. 1a ).
Previously, it was shown that hypomethylation induced by 5-azacytidine increases estrogenindependent growth 29 , which suggests a general mechanism whereby loss of methylation in breast tumors could contribute to estrogen-independent growth and thus endocrine therapy resistance.
LTED Cells Up-regulate ERα response genes and Potential Resistance Genes.
RNA-seq analysis indicated 443 up-and 353 down-regulated genes in MCF7-LTED cells relative to MCF7. We searched the promoters of up-and down-regulated genes for changes in methylation from 500 bp upstream to 1 kb downstream of the transcription start sites, since these regions often correlate with gene expression changes 30, 31 . We identified seven genes with promoter methylation changes that associated with expression changes. Identified genes included PTGER4 and WISP2 (Supplementary table 1). We validated correlations by examining whether differentially methylated regions correlated with expression across 632 breast tumors and 98 normal breast tissue samples from The Cancer Genome Atlas (TCGA, Supplementary Fig. S4 ).
WISP2 showed a marked increase in methylation 3' of the TSS, which was accompanied by a dramatic decrease in expression ( Fig. 1c ). It was previously shown that knockdown of WISP2, a WNT-signaling interacting protein, promoted estrogen-independent growth in MCF7 cells 32 .
WNT-signaling has been frequently implicated in epithelial-mesenchymal transition (EMT), and ontology pathway analysis indicated that genes up-regulated in MCF7-LTED cells were enriched for TGF-beta dependent induction of EMT. However, visual inspection of MCF7-LTED cells did not indicate an obvious EMT phenotype and loss of E-cadherin expression was not observed based on RNA-seq data.
Instead, we focused on the PTGER4 gene that encodes the EP4 receptor. We chose EP4 because it showed the largest expression increase of the candidates, showed a strong and clear change in methylation, and PTGER4 presents a potential druggable target. EP4 is a G-protein coupled receptor that activates AC and PKA in response to prostaglandin E 2 (Yokoyama et al., 2013) .
The PTGER4 gene has a CpG island associated with its promoter that lost methylation in the transition from MCF7 to MCF7-LTED cells (Fig. 1b ). Methylation changes were validated using Methyl-Screen ( Supplementary Fig. S2a ) 34 . This loss of methylation is accompanied with a greater than 20-fold gain in PTGER4 expression as indicated by RNA-seq ( Fig. 1b , Parental cpm = 1.9, 8.9; LTED cpm = 226.4, 175.5) and confirmed by RT-qPCR ( Supplementary Fig. S2b ).
Furthermore, MCF7 cells treated with 5-azacytidine expressed higher levels of PTGER4 33 , consistent with the hypothesis that DNA hypomethylation directly regulates expression.
Increased mRNA levels in MCF7-LTED cells were accompanied with increases in EP4 protein expression as observed by immunofluorescence ( Fig. 1d ). Increased EP4 expression in MCF7
LTED cells was also accompanied by increased cAMP in response to the EP4 agonist L-902,688 ( Fig. 3b ).
EP4 inactivation decreases estrogen-independent cell growth in MCF7-LTED cells
We sought to determine whether EP4 knockdown would affect the ability of MCF7-LTED cells to grow in the absence of estrogen. EP4 was stably knocked down using lentiviral shRNAs in both MCF7 and MCF7-LTED cells. Visual inspection indicated shEP4 drastically reduced cell proliferation in comparison to a scrambled shRNA control. We further quantified the severe attenuation in growth using reduction in alamarBlue ( Supplementary Fig. S3 ). To better characterize this initial finding, we knocked down mRNA expression using two EP4-targeted siRNAs, and measured relative cellular proliferation seven days after transfection. We verified knockdown at the mRNA level by RT-qPCR ( Fig. 2b ). Since appropriate antibodies could not be found for Western blot analysis, we validated a decrease in EP4 protein by immunofluorescence ( Fig. 2d ) and by measurement of the secondary messenger cAMP, which is produced as a result of EP4 activity ( Fig. 2c ). MCF7-LTED cells treated with siRNAs targeting EP4 mRNA showed a 61% and 59% average reduction in cell proliferation relative to control siRNAs (p < 10 -7 for each siRNA, Fig. 2a ). These siRNAs showed no effect in MCF7 cells, which have negligible levels of EP4 expression at the mRNA and protein levels and thus provide a control for off-target effects.
We further validated the importance of EP4 for estrogen-independent growth in MCF7-LTED cells using two EP4-specific antagonists that do not inhibit other prostaglandin receptor subtypes: GW627368X and ONO-AE3-208. We observed an average 32% reduction in cellular proliferation for GW627368X-treated and an average 38% reduction for ONO-AE3-208-treated MCF7-LTED cells relative to vehicle alone (p < 10 -7 for each antagonist, Fig. 2e ). Again, MCF7 cells, which have negligible EP4 expression, showed no significant proliferation reduction when treated with antagonists.
Functional analysis of EP4 signaling in MCF7-LTED cells
EP4 activates two pro-growth signaling pathways: PI3K and PKA; both of which could promote endocrine therapy resistance. MCF7-LTED cells show increased Akt and PI3K activity, and short-term estrogen deprived MCF7 cells are sensitive to the BGT226 and BKM120 PI3K inhibitors 24 . Additionally, EP4 activation can result in phosphorylation and activation of Akt 27 .
However, our MCF7-LTED cells are resistant to the effects of the BGT226 and BKM120 PI3K inhibitors 24 . Analysis of Akt and PI3K phosphorylation also showed no changes after treatment of MCF7-LTED cells with EP4 antagonists (Fig. 3a ). In addition, we did not find changes in mTOR or MAPK signaling. This suggests that other pathways are likely activated by EP4 in our MCF7-LTED model.
We next hypothesized that PTGER4 might contribute to endocrine therapy resistance via AC.
EP4 activates AC in addition to Akt, and AC activity can induce ERα phosphorylation. Once activated AC produces cAMP as its secondary messenger, and cAMP promotes proliferation through downstream effectors such as PKA 27 . We observed that both the concentration of cAMP in LTED cells and cell proliferation decreased after EP4 reduction by siRNA knockdown (Fig.   2a ,c). This suggested that EP4 promotes proliferation in LTED cells via AC and cAMP. To confirm this conclusion, we applied the EP4 specific agonist L-902,688 to MCF7-LTED cells and observed a dramatic increase in cAMP which went away upon inhibition of EP4 with antagonists ( Fig. 3b ).
A recent report showed that cAMP activates CARM1 via phosphorylation by PKA and drives ligand-independent ER transcriptional activity to promote resistance to tamoxifen 35 . CARM1 is an estrogen-dependent ER co-activator and phosphorylated CARM1 binds directly to ERα 36 . We thus tested whether a similar mechanism caused ligand independent ER signaling in MCF7-LTED cells. CARM1 proteins levels remained unchanged in MCF7-LTED and parental cells in the absence of estrogen even after treatment with EP4 antagonist (Fig. 3c ). We found however that CARM1 acted as a PKA substrate in MCF7-LTED cells in the absence of estrogen and this interaction went away after treatment with EP4 antagonist. We further found that ERα showed a strong interaction between CARM1 and ERα in MCF7-LTED cells based on immunoprecipitation of CARM1 followed by immunoblotting with an ERα-specific antibody ( Fig. 3c ). Treatment with EP4 antagonist removed this interaction, suggesting that the CARM1-ERα interaction is dependent on EP4 signaling. As has been reported previously 36 , in estrogen deprived conditions MCF7 cells showed no activation of CARM1 or association with ERα.
We next used chromatin-immunoprecipitation (ChIP)-qPCR to interrogate the relationship between EP4 and ligand independent binding of ERα in MCF7-LTED cells at two ERα binding sites, the pS2 and PGR promoters. MCF7-LTED cells were treated with agonist or vehicle and subjected to ChIP-qPCR with antibodies to CARM1 or ERα at the pS2 promoter, the PGR promoter, and a negative control gene desert region on chr8q24 ( Fig. 3c,d ). Both CARM1 and
ERα were found to have increased binding upon treatment with EP4-specific agonist relative to cells treated with vehicle. No such gain was observed in the gene desert region. This implies that EP4 signaling can activate ligand-independent ER activation mediated through CARM1.
ER signaling in MCF7-LTED cells
To understand whether ligand-independent ER signaling is active in MCF7-LTED cells, we compared gene expression in MCF7-LTED cells relative to MCF7 cells that recovered with the addition of estradiol after short-term estrogen deprivation (1 day) using RNA-seq. Using MCF7 cells treated with estradiol we defined a signature of ER signaling based on genes up-regulated two-fold or more. Gene Set Enrichment Analysis (GSEA) 37 shows that the majority of ER responsive genes are also up-regulated in MCF7-LTED (p < 10 -7 , Supplementary Fig. S6 ). This is consistent with the finding that our MCF7-LTED cells are responsive to the ER-antagonist fulvestrant 24 and indicates that ligand-independent ER-signaling is active in MCF7-LTED cells at a genomic level.
EP4 mRNA expression increased in ER+ breast cancer in the neoadjuvant setting
To assess the potential clinical relevance of our findings, we tested the hypothesis that EP4 expression increases are associated with initial sensitivity to aromatase inhibitor endocrine therapies. Expression profiling was performed for 104 patients before and after neoadjuvant aromatase inhibitor therapy. 74 tumors were determined as 'aromatase-inhibitor-resistant' and 30
as 'aromatase-inhibitor-sensitive' based on the presence of the proliferation marker Ki67 after treatment (see details in methods). Ki67 is a well-established indicator of clinical outcome in the neoadjuvant setting 38 . We observed that EP4 expression was higher in patients that demonstrated resistance to AI-therapy versus patients that responded to AI-therapy, which is consistent with EP4 expression playing a role in AI-resistance. Interestingly, EP4 expression also significantly increased during neoadjuvant therapy in both responder and non-responder tumor sample. Data from two smaller studies examining mRNA changes during neoadjuvant therapy verify this finding 39, 40 (Fig. 4 ). This suggests that in addition to promoting resistance to AIs, EP4 activation may be a response to the loss of ER signaling in ER+ tumors.
Discussion
In this study we examined the potential for DNA methylation to facilitate acquired endocrine therapy resistance via EP4 signaling. EP4 signaling also contributes to the proliferation of several cancer types including colon, lung, prostate, ovarian and breast 27 . Antagonists of EP4
have been shown to inhibit metastasis in hormone-resistant murine mammary tumor cells 41 .
Further, the contribution of EP4 to endocrine therapy resistance via cell signaling is consistent with its role in the development of castration-resistant prostate cancer via PKA and cAMP 42 .
While our results point to epigenetic regulation of EP4, mutations are unlikely to play a major role in its activation. According to the COSMIC database, EP4 mutations are exceedingly rare in breast cancer, occurring in 0.33% of patients and copy number gains in 1.5% 45 . Sanger sequencing of PTGER4 in both MCF7 and MC7-LTED cells failed to uncover any mutations that could contribute to the increased activation of EP4. However, analysis of TCGA data indicates that PTGER4 methylation appears to accompany gene silencing in many breast tumors ( Supplementary Fig. S4 ). Interestingly, PTGER4 is unmethylated and expressed in normal breast tissue. MCF7 cells treated with demethylating agents increase PTGER4 mRNA levels, consistent with DNA methylation playing a direct role in its transcriptional regulation 33 . This supports a mechanism whereby an upstream epigenetic change in the EP4 promoter regulates PTGER4 expression. Namely an increase in DNA methylation that silences PTGER4 as the tumor forms followed by a decrease in methylation that reactivates the gene to promote resistance to estrogen withdrawal in long-term estrogen deprived cells ( Fig. 1) .
Increased EP4 levels induce increased cAMP production, which drives ligand-independent activation of ER through the PKA-mediated activation of the co-activator CARM1. Prior work has also indicated that PKA can activate ERα by direct phosphorylation of serines 236 (S236) and 305 (S305). When S236 is phosphorylated, ERα dimerization and DNA binding is still dependent on ligand 36 and thereby S236 phosphorylation is unlikely to activate ERα in MCF7-
LTED cells. Studies in HeLa cells using a phosphomimetic S305E ERα suggested that S305
phosphorylation was sufficient to induce ligand-independent ERα binding to transcriptional targets in the absence of ERα dimerization 43 . However, other studies have instead suggested that S305 phosphorylated ERα is insufficient for ERα activation and that cofactors such as as CARM1 35 in MCF7 cells and CREB 44 in CHO were required for ERα binding to DNA and activation of response elements. While we cannot rule out the direct activation of ERα by PKA nor the activation of additional cofactors, our observations suggest that in estrogen deprived conditions EP4 promotes ligand independent activation of ERα through the PKA-mediated activation of the co-activator CARM1.
Another potential mechanism of ligand-independent ER activation is through genetic alterations of the ESR1 locus. While any individual event is quite rare, as a whole these alterations are becoming an important theme in resistance. Metastatic tumors gain activating ESR1 ligand binding domain mutations, especially after endocrine therapy 6, [46] [47] [48] [49] . Translocations of the ESR1 locus can fuse with activating coding sequence or constitutive promoters that activate ESR1 in the absence of estrogen 6 . ESR1 amplification has also been noted in both MCF7-LTED cells 7 and a xenograft line from a patient tumor resistant to AIs 6 . Rather than contradict our findings, however, this indicates that MCF7-LTED cells remain dependent on ERα signaling. Indeed, MCF7-LTED cells are sensitive to fulvestrant, an ER antagonist that accelerates proteasomal degradation of ER, indicating that these cells remain reliant on ER signaling 24 . GSEA analysis of
RNA-seq data from MCF7-LTED cells further shows that MCF7-LTED cells show increased
expression of ER target genes. Further, we did not observe a dramatic shift in DNA methylation changes at ER binding sites, which are a surrogate for altered ER binding.
Altogether, these data suggest that increased EP4 expression represents a viable means of developing resistance to aromatase inhibitor therapy. Expression increases in PTGER4 were associated with decreases in DNA methylation, which is consistent with the idea that DNA methylation has a regulatory role in PTGER4 expression. Our data indicate that EP4 activation is necessary for estrogen-independent growth. While we cannot completely rule out activation of alternative signaling pathways, our results support the conclusion that EP4 acts through PKA and the co-activator CARM1 to drive ligand-independent ERα activation. EP4 signaling presents a potential therapeutic target for the treatment of AI-resistant breast cancer.
Materials and Methods
MCF7 and MCF7-LTED cells
MCF7 cells were from the American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 (Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 5% FBS (Gibco), 10 mM HEPES (Corning, Manassas, VA) , 4.5 g/L glucose (Corning), 2 mM L-glutamine (Gibco), 1 mM sodium pyruvate (Corning), and 50 µg/ml gentamicin (Gibco) in a humidified 37°C incubator containing 5% CO 2 . MCF7-LTED cells were previously derived from MCF7 cells 24 and maintained in the same media except with 5% charcoal stripped FBS (Gibco) and RPMI 1640 without phenol red (Gibco).
Methyl-MAPS genome-wide methylation analysis
Methyl-MAPS analysis was performed as in Edwards et al. with custom barcoded adaptors 28 .
Libraries were made with AB-SOLiD and paired-end sequenced. Sequencing reads were demultiplexed and analyzed using custom perl scripts 28 . Sequencing statistics are in Supplementary Fig. S1 .
RNA-seq
RNA-seq libraries were prepared using NEB Next RNA-seq kit (NEB, Ipswich, MA) with custom barcodes and sequenced with an Illumina HiSeq. Reads were demultiplexed using custom perl scripts. Sequencing statistics are in Supplementary Fig. S1 . Reads were mapped to the human genome (hg18) using TopHat (v1.4) 50 . HT-seq was used to assign RefSeq annotations the reads 51 . Statistical analysis was performed using EdgeR 52 . Ontology analysis was performed with Metacore.
Immunofluorescence
Images were captured on a Zeiss AxioImager Z1 with AxioCam MRc and Axiovision software.
The primary antibody was Cayman Chemical Company (Ann Arbor, MI) 101775. The secondary antibody was Jackson ImmunoResearch (West Grove, PA) 111-545-003.
RT-qPCR
Ep4 mRNA expression was assessed using Applied Biosystems Viia7 with SYBR green. Primer information is in Supplementary Table S1 . All qPCR measurements were performed in triplicate.
Methyl-Screen
Methyl-screen analysis was performed as in Holemon et al. 34 
Cell proliferation
shRNA targeting EP4 mRNA were from the RNAi core at Washington University in St. Louis.
Silencer Select siRNAs were from Ambion (Thermo Fisher Scientific; siCtrl, 4390846; siEP4, 4427037; siEP4-1, ID s60396; siEP4-2, ID s11456). siRNAs were transfected with Lipofectamine RNAiMax (Invitrogen, Thermo Fisher Scientific). When specified, EP4
antagonist GW627368X was used at 3.3 μM and ONO-AE3-208 was used at 10 μM.
AlamarBlue assays were performed at 7 days for MCF7-LTED and 4 days for MCF7 cells. Onetenth volume of alamarBlue reagent (AbD Serotec BUF012, Bio-Rad, Oxford, UK) was added to each replicate. Eight replicates were performed for MCF7-LTED cells and 4 replicates for MCF7 cells. p-values were computed using a one-way ANOVA followed post-hoc by Tukey's HSD (honest significant difference) test. Bartlett's test of the homogeneity of variances was insignificant (alpha = 0.05) for all comparisons under the null-hypothesis of unequal variances.
ChIP-qPCR
Cells were grown in 10 cm dishes to 85% confluence. The cells were starved, by exchanging growth media for reduced-serum media containing 0.5% charcoal stripped FBS, for 18 hours before activation of EP4 with 10nM L902,688 EP4 agonist (Cayman Chemical) Real-time quantitative PCR was performed on an Applied Biosystems Viia7 using SYBR green.
Primers are in Supplementary Table S2 . 
The Cancer Genome Atlas data analysis
Infinium 450k methylation, RNA-seq expression and clinical data were downloaded from the The Cancer Genome Atlas (TCGA) data portal. P-values were computed using Mann-Whitney U.
Expression Analysis of ER+ breast cancer in neoadjuvant setting
Expression analysis was performed for patients enrolled in the POL 53 
Expression analysis was performed using Agilent Human Gene Expression 4x44K v2
Microarray. P-values for PTGER4 expression were computed using Mann-Whitney U. 
